Cardio-oncology
Overview
Cardio-oncology is a scientific journal, published by Biomed Central since 2015 in English. The journal's country of origin is United Kingdom and its primary focus area is oncology.
Details
Details
Abbr.
Cardiooncology
Publisher
Biomed Central
Start
2015
End
Continuing
e-ISSN
2057-3804
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 12197
21
SJR / Ranks: 4081
958
CiteScore / Ranks: 4502
5.40
Recent Articles
11.
Soosaipillai A, Nardi-Agmon I, Brinc D, Fabros A, Kavsak P, Thavendiranathan P, et al.
Cardiooncology
. 2025 Feb;
11(1):18.
PMID: 39953627
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is an important adverse effect in patients receiving potential cardiotoxic cancer therapies. Interpretation of cardiac troponin results can be affected by presence of macrotroponin,...
12.
Lal J, Fang M, Hussain M, Abraham A, Tonegawa-Kuji R, Hou Y, et al.
Cardiooncology
. 2025 Feb;
11(1):17.
PMID: 39948601
Background: Cancer-therapy related cardiac dysfunction (CTRCD) remains a significant cause of morbidity and mortality in cancer survivors. In this study, we aimed to identify differential plasma proteins and metabolites associated...
13.
Xu S, Sonkawade S, Karthikeyan B, Karambizi V, Kulkarni P, Nepali S, et al.
Cardiooncology
. 2025 Feb;
11(1):16.
PMID: 39940032
Background: Myocarditis is a potentially fatal condition, with a mortality rate of up to 50% in severe cases. Studies, including those by Nobel Laureate Honjo, have implicated autoantibodies against cardiac...
14.
Simela C, Walker J, Ghosh A, Chen D
Cardiooncology
. 2025 Feb;
11(1):15.
PMID: 39934910
More evidence-based strategies are needed for preventing and managing cancer treatment-related cardiovascular toxicity (CTR-CVT). Owing to the growing body of evidence supporting their cardioprotective role in several cardiac injury scenarios,...
15.
Kruger D, Pannucci P, Wesley C, Neutel C, Martinet W, De Meyer G, et al.
Cardiooncology
. 2025 Feb;
11(1):14.
PMID: 39934897
Background: Tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) receptor signalling are used in cancer therapy to inhibit angiogenesis. Unfortunately, VEGF inhibitors are known to induce severe hypertension...
16.
Labib D, Haykowsky M, Sonnex E, Mackey J, Thompson R, Paterson D, et al.
Cardiooncology
. 2025 Feb;
11(1):13.
PMID: 39923094
Background: This study investigates the long-term cardiac effects of trastuzumab-based chemotherapy in early breast cancer (EBC) survivors. We extend the original MANTICORE trial which showed that angiotensin-converting enzyme inhibitors (ACEI)...
17.
Lucas A, Bastiach D, Dahman B, Paul A, Hirani S, Sheppard V, et al.
Cardiooncology
. 2025 Feb;
11(1):12.
PMID: 39915845
Background: Androgen deprivation therapy (ADT) is the cornerstone treatment strategy for men diagnosed with high-risk prostate cancer (PC) but may increase risk for major adverse cardiovascular events (MACE). We examined...
18.
Sutton A, OConnell N, Lucas A, Olson K, Reding K, Sheppard V, et al.
Cardiooncology
. 2025 Feb;
11(1):11.
PMID: 39910652
Cancer survivors receiving doxorubicin may experience left ventricular ejection fraction (LVEF) decline during and following treatment; however, explanations for variations in decline beyond dosage differences, such as those related to...
19.
Soh C, Smith J, Shrestha S, Nolan M, Wong J, Nerlekar N, et al.
Cardiooncology
. 2025 Feb;
11(1):10.
PMID: 39905553
Background: Cancer survivors are reported to be at a heightened risk of coronary artery disease (CAD) due to shared risk factors, potentially cardiotoxic cancer treatments and premature aging in survivors....
20.
Amin A, Ghaly R, Elbenawi H, Ewis A, Khan U, Elshaer K, et al.
Cardiooncology
. 2025 Jan;
11(1):9.
PMID: 39885521
Background: Heart failure (HF) is associated with systemic inflammation and hypercatabolic syndrome, impacting body metabolism. The advanced lung cancer inflammation index (ALI) is a novel inflammatory and nutritional biomarker. We...